Reuters UKAstraZeneca Buys Rights to Synairgen Asthma CompoundGenetic Engineering NewsAstraZeneca signaled today it will take no breather from smaller, targeted “bolt-on” deals by in-licensing Synairgen’s clinical-phase drug SNG001, in a deal that could net Synairgen up to $232.25 million and should shore up the pharma giant’s respiratory …AstraZeneca extends global shopping spree with $232M asthma drug dealFierceBiotechUPDATE 1-AstraZeneca builds pipeline with $232 mln Synairgen asthma dealReutersAstraZeneca Announces Global Licence deal With Synairgen – quick factsRTT NewsPMLiVE -WTAQall 35 news articles …Read Full Story
AstraZeneca Buys Rights to Synairgen Asthma Compound - Genetic Engineering News
Real Estate of Cebu
